| Literature DB >> 35430460 |
Alfredo Lara-Morales1, Ana Gandarillas-Grande2, Antonio Díaz-Holgado3, Pilar Serrano-Gallardo4.
Abstract
AIM: To explore the influence of anxiety/depression symptoms and social risk in patients older than 65 years with type 2 diabetes mellitus (T2DM) both in non-adherence to pharmacological treatment (Non-AdhT) and in poor control of T2DM.Entities:
Keywords: Adherencia al tratamiento; Aging; Atención Primaria de Salud; Diabetes mellitus; Envejecimiento; Mental health; Patient compliance; Primary Health Care; Riesgo social; Salud mental; Social risk; Tipo 2; Type 2
Mesh:
Year: 2022 PMID: 35430460 PMCID: PMC9036116 DOI: 10.1016/j.aprim.2022.102302
Source DB: PubMed Journal: Aten Primaria ISSN: 0212-6567 Impact factor: 2.206
Patient characteristics, global and by sex.
| Global | Men | Women | |
|---|---|---|---|
| 884 | |||
| Men | 35.3 (312) | ||
| Women | 64.7 (572) | ||
| 884 | |||
| 66–79 | 23.4 (207) | 28.2 (88) | 20.8 (119) |
| 80–84 | 30.8 (272) | 33.0 (103) | 29.6 (169) |
| 85+ | 45.8 (405) | 38.8 (121) | 49.7 (284) |
| 884 | |||
| Spain + OECD | 98.8 (873) | 98.4 (307) | 99.0 (566) |
| Other countries | 1.2 (11) | 1.6 (5) | 1.1 (6) |
| 874 | |||
| No | 70.2 (614) | 81.0 (252) | 64.3 (362) |
| Yes | 29.8 (260) | 19.0 (59) | 35.7 (201) |
| 884 | |||
| Group 1 | 24.2 (214) | 27.9 (87) | 22.2 (127) |
| Group 2 | 38.0 (336) | 40.4 (126) | 36.7 (210) |
| Group 3 | 25.9 (229) | 23.1 (72) | 27.5 (157) |
| Group 4 | 11.9 (105) | 8.6 (27) | 13.6 (78) |
| 658 | |||
| Low weight/normal weight | 21.9 (144) | 21.8 (56) | 21.9 (88) |
| Overweight | 40.9 (269) | 47.5 (122) | 36.7 (147) |
| Obesity | 37.2 (245) | 30.7 (79) | 41.4 (166) |
| 744 | |||
| No | 27.6 (205) | 15.9 (44) | 34.4 (161) |
| Yes | 72.4 (539) | 84.1 (232) | 65.6 (307) |
| 884 | |||
| ≤5 years | 15.7 (139) | 16.0 (50) | 15.6 (89) |
| 6–10 years | 23.0 (203) | 24.7 (77) | 22.0 (126) |
| 11–15 years | 38.6 (341) | 39.7 (124) | 37.9 (217) |
| >15 years | 22.7 (201) | 19.6 (61) | 24.5 (140) |
| 884 | |||
| No | 74.9 (662) | 82.0 (256) | 71.0 (406) |
| Yes | 25.1 (222) | 18.0 (56) | 29.0 (166) |
Figure 1Prevalence of non-adherence to pharmacological treatment and poor Type 2 Diabetes Mellitus control, with 95% confidence interval, global and by sex.
OR for non-adherence to pharmacological treatment based on the characteristics of the sample for each sex and global.
| Men | Women | Global | |||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95%CI | OR | 95%CI | OR | 95%CI | ||||
| Women | 1.44 | 0.75–2.76 | 0.270 | ||||||
| 66–79 | 1.15 | 0.34–3.91 | 0.817 | 1.91 | 0.69–5.25 | 0.210 | 1.60 | 0.73–3.48 | 0.237 |
| 80–84 | 1.19 | 0.37–3.79 | 0.774 | 1.12 | 0.39–3.22 | 0.826 | 1.20 | 0.55–2.61 | 0.645 |
| Yes | 2.48 | 0.88–7.00 | 0.086 | 2.23 | 0.95–5.27 | 0.066 | 2.10 | 1.10–4.01 | 0.025 |
| Group 2 | 1.04 | 0.28–3.79 | 0.956 | 1.35 | 0.46–3.98 | 0.587 | 1.21 | 0.53–2.77 | 0.646 |
| Group 3 | 2.23 | 0.63–7.96 | 0.215 | 0.97 | 0.29–3.25 | 0.960 | 1.37 | 0.57–3.28 | 0.478 |
| Low weight/normal weight | 1.09 | 0.19–6.15 | 0.920 | 1.71 | 0.48–6.08 | 0.407 | 1.48 | 0.54–4.05 | 0.450 |
| Obesity | 2.42 | 0.66–8.88 | 0.181 | 1.44 | 0.46–4.50 | 0.532 | 1.75 | 0.74–4.12 | 0.200 |
| No | 4.42 | 1.45–13.45 | 0.009 | 2.84 | 1.06–7.60 | 0.038 | 2.96 | 1.43–6.10 | 0.003 |
| 11–15 years | 0.63 | 0.20–1.97 | 0.421 | 1.33 | 0.45–3.91 | 0.600 | 0.93 | 0.43–2.01 | 0.850 |
| >15 years | 1.04 | 0.30–3.61 | 0.946 | 2.11 | 0.72–6.22 | 0.175 | 1.49 | 0.67–3.28 | 0.325 |
| Yes | 4.57 | 1.68–12.45 | 0.003 | 1.73 | 0.73–4.14 | 0.215 | 2.41 | 1.26–4.63 | 0.008 |
The reference category of each variable is shown in parentheses; 95% CI: 95% confidence interval.
Multivariate logistic regression models of non-adherence to pharmacological treatment.
| Men ( | OR | 95%CI | |
|---|---|---|---|
| 66–79 | 2.41 | 0.56–10.30 | 0.236 |
| 80–84 | 1.79 | 0.43–7.52 | 0.424 |
| Group 2 | 0.74 | 0.17–3.25 | 0.695 |
| Groups 3–4 | 1.70 | 0.43–6.67 | 0.447 |
| No | 3.45 | 1.04–11.46 | 0.044 |
| Yes | 3.88 | 1.15–13.07 | 0.029 |
The reference category of each variable is shown in parentheses; 95% CI: 95% confidence interval.
OR for poor Type 2 Diabetes Mellitus control based on the characteristics of the sample for each sex and global.
| Men | Women | Global | |||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | 95%CI | OR | 95%CI | OR | 95%CI | ||||
| Women | 1.09 | 0.82–1.45 | 0.549 | ||||||
| 80–84 | 1.31 | 0.72–2.38 | 0.383 | 1.01 | 0.62–1.65 | 0.958 | 1.13 | 0.77–1.64 | 0.540 |
| 85 y más | 1.27 | 0.71–2.27 | 0.422 | 1.08 | 0.69–1.68 | 0.740 | 1.16 | 0.82–1.65 | 0.398 |
| Yes | 1.07 | 0.59–1.93 | 0.821 | 0.77 | 0.54–1.11 | 0.163 | 0.86 | 0.63–1.16 | 0.328 |
| Group 1 | 1.06 | 0.60–1.87 | 0.853 | 0.91 | 0.58–1.42 | 0.666 | 1.24 | 0.76–2.03 | 0.386 |
| Group 2 | 1.28 | 0.67–2.44 | 0.452 | 0.82 | 0.51–1.33 | 0.424 | 1.20 | 0.76–1.90 | 0.439 |
| Group 3 | 0.80 | 0.31–2.04 | 0.641 | 0.76 | 0.43–1.37 | 0.366 | 1.20 | 0.74–1.96 | 0.456 |
| Overweight | 1.86 | 0.88–3.89 | 0.102 | 1.51 | 0.86–2.65 | 0.146 | 1.59 | 1.02–2.48 | 0.039 |
| Obesity | 2.63 | 1.21–5.73 | 0.015 | 1.35 | 0.78–2.34 | 0.290 | 1.71 | 1.09–2.67 | 0.020 |
| No | 1.97 | 1.03–3.78 | 0.040 | 0.72 | 0.48–1.08 | 0.114 | 0.95 | 0.68–1.33 | 0.776 |
| 11–15 years | 2.07 | 1.21–3.55 | 0.008 | 2.61 | 1.74–3.93 | 0.000 | 2.40 | 1.74–3.33 | 0.000 |
| >15 years | 2.69 | 1.41–5.12 | 0.003 | 2.57 | 1.63–4.06 | 0.000 | 2.60 | 1.80–3.77 | 0.000 |
| Yes | 0.99 | 0.54–1.81 | 0.975 | 0.83 | 0.57–1.22 | 0.345 | 0.89 | 0.65–1.22 | 0.458 |
| Yes | 4.68 | 1.60–13.65 | 0.005 | 0.76 | 0.30–1.88 | 0.548 | 1.64 | 0.86–3.12 | 0.132 |
The reference category of each variable is shown in parentheses; 95% CI: 95 confidence intervals.
Multivariate logistic regression models of poor control of Type 2 Diabetes Mellitus.
| Men ( | OR | 95%CI | |
|---|---|---|---|
| 80–84 | 1.55 | 0.77–3.13 | 0.223 |
| 85 and more | 1.42 | 0.69–2.92 | 0.341 |
| Group 1 | 0.84 | 0.30–2.37 | 0.736 |
| Group 2 | 0.81 | 0.30–2.21 | 0.682 |
| Group 3 | 0.55 | 0.18–1.65 | 0.289 |
| Overweight | 2.09 | 0.96–4.53 | 0.063 |
| Obesity | 3.81 | 1.61–9.02 | 0.002 |
| 11–15 years | 2.69 | 1.40–5.17 | 0.003 |
| >15 years | 3.43 | 1.60–7.37 | 0.002 |
| 3.53 | 1.04–12.02 | 0.043 | |
| Women ( | OR | 95%CI | |
| 80–84 | 0.92 | 0.56–1.51 | 0.801 |
| 85 and more | 1.1 | 0.68–1.68 | 0.686 |
| Group 1 | 1.38 | 0.76–2.52 | 0.495 |
| Group 2 | 1.28 | 0.73–2.23 | 0.602 |
| Group 3 | 1.09 | 0.61–1.95 | 0.627 |
| 11–15 years | 2.67 | 1.77–4.05 | 0.000 |
| >15 years | 2.64 | 1.67–4.18 | 0.000 |
| Global ( | OR | 95%CI | |
| 80–84 | 0.98 | 0.63–1.51 | 0.91 |
| 85 and more | 1.15 | 0.75–1.75 | 0.527 |
| Group 1 | 0.97 | 0.53–1.77 | 0.924 |
| Group 2 | 0.92 | 0.52–1.63 | 0.781 |
| Group 3 | 0.58 | 0.32–1.07 | 0.082 |
| Overweight | 1.74 | 1.10–2.75 | 0.018 |
| Obesity | 2.12 | 1.32–3.41 | 0.002 |
| 11–15 years | 2.71 | 1.83–4.02 | 0.000 |
| >15 years | 2.88 | 1.83–4.54 | 0.000 |
| Men with non-adherence | 3.75 | 1.12–12.60 | 0.033 |
| Women with adherence | 1.19 | 0.83–1.70 | 0.333 |
| Women with non-adherence | 0.88 | 0.31–2.50 | 0.804 |
The reference category of each variable is shown in parentheses; 95% CI: 95% confidence interval.